Testing a new cancer drug to block DNA repair

Plain-English translation of NCT06395519 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new drug called in people with advanced solid cancers. The medication works by targeting a protein that cancer cells rely on to repair their DNA damage. By blocking this protein, the treatment aims to make cancer cells more vulnerable and stop them from growing.

Many cancers develop special abilities to survive damage that would normally kill cells. This medication is designed to exploit a weakness in how cancer cells handle that damage, offering a new approach for people whose cancers have stopped responding to standard treatments.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced or metastatic solid cancer (any type except brain tumors) that has stopped responding to or worsened after standard treatment
you have measurable cancer that can be tracked on imaging scans
you are in good enough health to participate (ECOG score 0–1)
you have a life expectancy of at least 3 months
you have not taken any experimental drugs in the past 2–3 weeks

You likely don't qualify if…

you are taking high-dose corticosteroids (more than 10 mg daily of prednisone equivalent)
you have had major radiation therapy in the past 6 weeks or palliative radiation in the past 2 weeks
you have active, untreated, or worsening brain metastases (stable, treated ones are okay)
you have a history of serious heart problems, abnormal heart rhythms, or long QT syndrome
you have severe digestive problems or conditions that prevent you from absorbing oral medication

What participation looks like

The trial has two main phases: first, researchers test increasing doses of the medication to find the safest and most effective dose, then additional participants receive that chosen dose. You would visit the study clinic regularly for blood tests, heart monitoring, and imaging scans to see how the medication is working. The medication is taken by mouth, and the study team will closely watch for side effects and how your cancer responds to treatment.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(14 sites)

United States

Mayo Clinic, Phoenix, Arizona

Yale University, Yale Cancer Center, New Haven, Connecticut

Mayo Clinic, Jacksonville, Florida

University of Chicago Medical Center, Chicago, Illinois

Massachusetts General Hospital, Boston, Massachusetts